Meeting
2017 ASCO Annual Meeting
Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).
Authors
Andrew Charles Dietz
Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA
Andrew Charles Dietz , Stephan A. Grupp , Theodore Willis Laetsch , Heather Stefanski , Gary Douglas Myers , Henrique Bittencourt , Jochen Buechner , Eneida R. Nemecek , Paul L. Martin , Hidefumi Hiramatsu , Francoise Mechinaud , Gregory A. Yanik , Barbara De Moerloose , Patricia Ann Wood , Lawrence Rasouliyan , Yiyun Zhang , Simu K. Thomas , Sweta Shah , Andrew Harris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT02435849
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10523)
DOI
10.1200/JCO.2017.35.15_suppl.10523
Abstract #
10523
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.
First Author: Jonathan Bender
Poster
2021 ASCO Annual Meeting
Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
First Author: Stephen J. Schuster
Poster
2020 ASCO Virtual Scientific Program
Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).
First Author: Joerg Krueger
Poster
2019 ASCO Annual Meeting
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.
First Author: Jessica Hochberg